JPMorgan Chase & Co. Has $317,000 Stock Position in Omeros Co. (NASDAQ:OMER)

JPMorgan Chase & Co. boosted its stake in shares of Omeros Co. (NASDAQ:OMER) by 31.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 32,134 shares of the biopharmaceutical company’s stock after purchasing an additional 7,667 shares during the period. JPMorgan Chase & Co. owned 0.06% of Omeros worth $317,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of OMER. Truvestments Capital LLC boosted its holdings in shares of Omeros by 116.5% in the 4th quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 1,669 shares during the last quarter. Quantbot Technologies LP acquired a new stake in Omeros in the fourth quarter valued at $46,000. Picton Mahoney Asset Management grew its position in shares of Omeros by 692.5% in the 4th quarter. Picton Mahoney Asset Management now owns 5,040 shares of the biopharmaceutical company’s stock valued at $50,000 after acquiring an additional 4,404 shares during the period. US Bancorp DE bought a new position in shares of Omeros in the 4th quarter valued at about $81,000. Finally, China Universal Asset Management Co. Ltd. bought a new stake in shares of Omeros in the 4th quarter valued at about $121,000. 48.79% of the stock is currently owned by institutional investors.

Omeros Trading Up 2.1 %

Omeros stock opened at $7.17 on Friday. The company has a market capitalization of $416.32 million, a price-to-earnings ratio of -3.10 and a beta of 2.35. Omeros Co. has a 12 month low of $3.00 and a 12 month high of $13.60. The stock’s 50 day moving average is $7.63 and its 200-day moving average is $8.05.

Omeros (NASDAQ:OMER) last posted its quarterly earnings data on Monday, March 31st. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, topping the consensus estimate of ($0.71) by $0.08. During the same period in the prior year, the firm posted ($0.15) EPS. As a group, equities research analysts predict that Omeros Co. will post -3.09 earnings per share for the current fiscal year.

Analysts Set New Price Targets

OMER has been the topic of a number of recent analyst reports. StockNews.com downgraded Omeros from a “hold” rating to a “sell” rating in a research report on Wednesday, April 9th. Needham & Company LLC reissued a “hold” rating on shares of Omeros in a report on Tuesday, April 1st. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $36.00 price target on shares of Omeros in a report on Friday, April 11th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $22.50.

Omeros Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.